Read Our Most Recent Shareholder Letter

Company Overview

With the acquisition of Sapphire Biotech, AXIM is a vertically integrated oncology company developing rapid diagnostic tests for the early detection of cancer, proprietary small molecules drugs not only to treat cancer but also to block metastasis and developing novel antibodies for therapeutic and diagnostic uses.

Investor Presentation

Email Alerts

Stay informed and receive company updates straight to your inbox

Recent News

AXIM® Biotechnologies Issues Update Letter to Shareholders

SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that it has issued a letter...

Latest Annual Filing

Fiscal Year Ended Dec 31, 2018

Investor Contact Information


AXIM Biotechnologies, Inc.
45 Rockefeller Plaza
20th Floor, Suite 83
New York, NY 10111
T: +1 858 923-4422

Investor Relations

Transfer Agent

Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088